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Abstract
Objective
To validate midregional proatrial natriuretic peptide (MR-proANP) for outcome prediction
and diagnosis of cardioembolic stroke etiology compared to established clinical variables.
Methods
In this prospective multicenter cohort study, we quantiﬁed MR-proANP levels in ischemic
stroke patients within 24 hours of onset. Primary outcome measures were 90-day mortality,
unfavorable functional outcome (modiﬁed Rankin Scale score >2), and cardioembolic stroke
etiology diagnosed during hospitalization.
Results
Of 788 included patients, 783 completed their 90-day follow-up, and 118 patients (15%) died.
After full adjustment, MR-proANP levels were associated with 90-day mortality (adjusted
hazard ratio 6.12, 95% conﬁdence interval [CI] 2.36–15.84, p = 0.01) and functional outcome
(adjusted odds ratio [aOR] 2.46, 95% CI 1.05–5.74, p = 0.038). For mortality prediction,
adding MR-proANP to the regression model increased its discriminatory accuracy, and the
continuous net reclassiﬁcation index (cNRI) was 49% (95% CI 26%–78%, p < 0.001). For
functional outcome, there was no signiﬁcant improvement in discrimination or reclassiﬁcation.
Cardioembolic stroke etiology and the diagnosis of atrial ﬁbrillation at hospital discharge were
associated withMR-proANPwith an aOR of 2.10 (95%CI 1.11–3.97, p = 0.02) and 18.35 (95%
CI 7.94–42.45, p < 0.001), respectively. The cNRI of MR-proANP for cardioembolic stroke
etiology was not signiﬁcant, as opposed to atrial ﬁbrillation (78%, 95%CI 60%–89%, p < 0.001).
MR-proANP levels ≥289 pmol/L had a speciﬁcity of 86% and sensitivity of 48% for the
diagnosis of atrial ﬁbrillation.
Conclusion
MR-proANP is a newly validated blood biomarker providing additional prognostic information
for mortality after stroke. HigherMR-proANP levels were associated with cardioembolic stroke
etiology and, even more strongly, atrial ﬁbrillation.
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Blood markers measured immediately after an acute ische-
mic stroke may represent important adjuncts to traditional
risk factors in the emergency setting. Tailoring treatment
based on reliably estimated risk may improve patient
outcome.
In routine clinical practice, blood biomarkers can be useful if
they improve the prognostic accuracy of established clinical
variables such as age and stroke severity.1,2 However, before
biomarkers are implemented in clinical practice, validation is
crucial, as shown by a meta-analysis suggesting that pilot
studies on blood biomarkers typically report higher eﬀect
sizes than subsequent larger validation studies of the same
blood marker.3
Previous monocentric studies have shown that midregional
proatrial natriuretic peptide (MR-proANP) is a promising
prognostic and diagnostic biomarker among patients with
acute ischemic stroke. In particular, MR-proANP improved
the discriminatory ability of the NIH Stroke Scale (NIHSS)
score4 for 90-day mortality.5 Through an independent, mul-
ticenter prospective cohort study, we aimed to validate the
accuracy of MR-proANP in predicting functional outcome
and mortality compared to established clinical variables.
Moreover, this study sought to evaluate the accuracy of MR-
proANP for identifying cardioembolic stroke and atrial
ﬁbrillation.
Methods
Standard protocol approvals, registrations,
and patient consents
This study (Copeptin for Risk Stratiﬁcation in Acute
Stroke Patients [CoRisk] study; clinicaltrials.gov,
NCT00878813) was conducted according to the princi-
ples expressed in the Declaration of Helsinki and was
approved by the local ethics committees. All patients or
their welfare guardians provided written informed consent
for the collection of data, blood samples, and subsequent
analyses.
Study design and cohort description
The methodology of this multicenter cohort study has been
published previously.6 Brieﬂy, the primary endpoint in-
cluded disability (modiﬁed Rankin Scale [mRS] score 3–5)
and mortality (mRS score 6) at 90 days after stroke. We
included patients >18 years of age with an acute ischemic
stroke within 24 hours of symptom onset admitted con-
secutively to the emergency department of each tertiary
care center between March 24, 2009, and April 8, 2011.
None of the patients enrolled in this study were part of
a previous cohort evaluating MR-proANP.5 We deﬁned
acute ischemic stroke according to the World Health Or-
ganization criteria as an acute focal neurologic deﬁcit last-
ing >24 hours with no sign of acute intracranial bleeding on
cerebral imaging.7 Neither MRI nor a lesion on diﬀusion-
weighted imaging (DWI) was mandatory for the diagnosis
of stroke.
Exclusion criteria were missing informed consent; TIAs
(duration ≤24 hours) regardless of DWI lesions, as
prespeciﬁed in the published protocol8; and any other di-
agnosis diﬀerent from ischemic stroke. Vascular neurolo-
gists prospectively recorded the NIHSS score on
admission. CT or MRI was performed in each patient.
MR-DWI was available for 537 stroke patients (68.5%).
DWI lesion volumes were measured by experienced
raters unaware of the clinical and laboratory ﬁndings. The
lesion size was calculated by a commonly used semi-
quantitative method as previously described.9 Lesions were
categorized into 3 size classes: small lesion with a volume of
<10 cm3, medium lesion with a volume of 10 to 100 cm3, or
large lesion with a volume >100 cm3.10 Demographic and
vascular risk factors were collected on admission. More-
over, comorbidities were assessed on admission by the
modiﬁed Charlson Comorbidity Index.11 Data on cardiac
and neurovascular ultrasound and 24-hour ECGs were
gathered to deﬁne stroke etiology according to the Trial of
Org 10172 in Acute Stroke Treatment (TOAST)
classiﬁcation.12
Biomarker measurement
Blood was drawn in the emergency room within 24 hours of
symptom onset. Samples were immediately centrifuged, di-
vided into aliquots, and frozen at −80°C until the time of
analysis. MR-proANP levels were assessed in plasma in
a blinded batch analysis with the automated B·R·A·H·M·S
KRYPTOR immunoassay technology (BRAHMS GmbH,
Hennigsdorf, Germany). The lower detection limit was 2.1
pmol/L, and the functional assay sensitivity was <10 pmol/L
(<20% interassay coeﬃcient of variation, deﬁned as the ratio
of the SD to the mean). MedianMR-proANP levels in healthy
controls were reported to be 46.1 pmol/L and the 97.5 per-
centile was at 85.2 pmol/L.13
Glossary
AUC = area under the ROC curve; BNP = brain natriuretic peptide; CI = conﬁdence interval; CoRisk = Copeptin for Risk
Stratiﬁcation in Acute Stroke Patients;DWI = diﬀusion-weighted imaging; eGFR = estimated glomerular ﬁltration rate; IQR =
interquartile range; MR-proANP = midregional proatrial natriuretic peptide; mRS = modiﬁed Rankin Scale; NIHSS = NIH
Stroke Scale;NRI = net reclassiﬁcation index;NT-proBNP =N-terminal probrain natriuretic peptide;OR = odds ratio;ROC =
receiver operating characteristic; TOAST = Trial of Org 10172 in Acute Stroke Treatment.
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Follow-up and outcome measures
Three months after stroke, vascular neurologists and trained
study nurses blinded to MR-proANP levels assessed outcome
either during an outpatient visit or with a structured telephone
interview. Unfavorable outcome was deﬁned as an mRS score
of 3 to 6 points. If patients died within the follow-up period,
the date of death was recorded. Cardioembolic stroke was
deﬁned according to the TOAST classiﬁcation. Furthermore,
atrial ﬁbrillation, as outcome variable, was deﬁned as diagnosis
of atrial ﬁbrillation at hospital discharge, thus encompassing
history of atrial ﬁbrillation on admission and newly diagnosed
atrial ﬁbrillation during hospitalization.
Statistical analysis
Discrete variables were expressed as counts (percentages) and
continuous variables as medians (interquartile range [IQR]).
Biomarker data were log-transformed to achieve normality. The
Shapiro-Wilk test was used to test for normality. Frequency
comparisons for categorical baseline measurements were per-
formed by the Fisher exact test. Two-group comparison of con-
tinuous, not normally distributed baseline data was performed by
the Mann-Whitney U test. We used the Bonferroni method to
correct p values for multiple univariate comparisons; i.e., we
multiplied the uncorrected p values by the number of compar-
isons. To investigate the association of MR-proANP with func-
tional outcome, cardioembolic etiology, and atrial ﬁbrillation, we
calculated logistic regression models, and for the association with
mortality, we computed Cox regression models. To illustrate the
mortality rate, patients were stratiﬁed by quartiles ofMR-proANP
levels, and Kaplan-Meier curves were computed and compared
with the log-rank test. Odds ratios (ORs), hazard ratios, and 95%
conﬁdence intervals (CIs) were calculated, unadjusted and ad-
justed for demographic and vascular risk factors. As covariates for
the multivariate models, we selected all the variables with a uni-
variate p <0.01 and, regardless of the p value, thrombolysis, heart
failure, and cardioembolic stroke for the models concerning
functional outcome and mortality. For cardioembolic stroke and
atrial ﬁbrillation as outcome, all the variables with a univariate p
<0.01 were included. Coronary heart disease was not included in
any model because of collinearity with atrial ﬁbrillation.
Interaction analyses were performed to investigate whether
the predictive value of MR-proANP is modiﬁed by sex, age,
stroke severity (NIHSS scores 0–6, 7–15, and >15), hyper-
tension, diabetes mellitus, atrial ﬁbrillation, heart failure, and
estimated glomerular ﬁltration rate (eGFR), categorized to
represent relevant renal disease (cutoﬀ <60 mL/min/
1.73 m2). The calibration of the logistic and Cox models was
assessed with the Hosmer-Lemeshow goodness-of-ﬁt test and
Groennesby and Borgan test, respectively.
Receiver operating characteristic (ROC) curves and area under
the ROC curve (AUC) as an overall discriminatory measure
were calculated. The De Long test was used to compare the
AUCs of 2 diﬀerent single variables, whereas the likelihood ratio
test was used to compare the AUCs of nested vs whole models.
The whole model included all predictors that remained
signiﬁcant in the multivariate model (p <0.05). In addition, we
calculated cutoﬀ ranges of MR-proANP (from 95% sensitivity to
95% speciﬁcity) for the main outcome measures (i.e., functional
outcome, mortality, cardioembolic stroke, and atrial ﬁbrillation).
To further estimate the additive beneﬁt of MR-proANP levels to
the traditional outcome predictor, we calculated the net reclas-
siﬁcation index (NRI) on the basis of the model including pre-
dictors that remained signiﬁcant in the multivariate model
(p <0.05). The NRI has been proposed to evaluate prognostic
biomarkers.2,14 To corroborate the ﬁndings, the change in the
(pseudo)R2 value (McFadden adjusted) of the regressionmodel
was determined by calculating a multivariate logistic regression
model with and without MR-proANP as a regressor for func-
tional outcome, mortality, and cardioembolic stroke. Statistics
were calculated with Stata Statistical Software, release 14.2
(StataCorp LP, College Station, TX, 2015). Testing was 2 tailed,
and values of p < 0.05 were considered statistically signiﬁcant.
Results
Baseline data
From March 24, 2009, through April 8, 2011, a total of 788
patients with an acute ischemic stroke were consecutively
included in the study. Overall, 783 patients completed their
90-day follow-up (follow-up rate 99.4%). The median age of
the cohort was 71 (IQR 61–80) years, and 298 (38%) were
women. Patient characteristics stratiﬁed by functional out-
come and mortality are summarized in table 1. In addition,
patient characteristics are summarized by tertiles of MR-
proANP (table e-1, http://links.lww.com/WNL/A111).
Prediction of functional outcome after
3 months
At 90 days, 300 patients (38.3%) had an unfavorable outcome
(mRS score 3–6). Median MR-proANP concentration was al-
most twice as high in patients with unfavorable than in thosewith
favorable outcomes (225 [IQR 126–359] vs 127 [IQR 79–224]
pmol/L, p < 0.001) (table 1 and ﬁgure e-1, http://links.lww.
com/WNL/A110). In themultivariate logistic regressionmodel,
MR-proANP levels were associated with an unfavorable out-
come (adjusted OR 2.46 for any 10-fold increase of MR-
proANP, 95%CI 1.05–5.74, p = 0.038). Additional predictors of
unfavorable outcome were age, stroke severity, eGFR, and large
lesion size on DWI, and after adjustment for cardioembolic
stroke and heart failure, MR-proANP remained associated with
functional outcome (table 2). Themultivariate models were well
calibrated according to the goodness-of-ﬁt test (Hosmer-
Lemeshow p = 0.4). No signiﬁcant interactions were found
across subgroups for the prediction of functional outcome.
MR-proANP improved only marginally the discriminatory ac-
curacy of the NIHSS and the whole multiple logistic regression
model (AUCchange from0.85 [95%CI 0.83–0.88] to 0.86 [95%
CI 0.83–0.88], p < 0.0071) (table 3 and ﬁgure e-2, http://links.
lww.com/WNL/A110). An MR-proANP level of 112 pmol/L
had a sensitivity of 81% and a speciﬁcity of 45% for functional
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Table 1 Patient characteristics
Total
Functional outcome at 90 d Mortality at 90 d
Favorable outcome
(mRS score 0–2)
Unfavorable outcome
(mRS score 3–6) p Value Bonferroni p value Alive Dead p Value Bonferroni p value
No. (%) 783 (100) 483 (62) 300 (38) 665 (85) 118 (15)
Demographic data
Age, median (IQR), y 71 (61–80) 66 (58–76) 77 (68–83) <0.001 <0.03 69 (59–78) 79 (71–85) <0.0001 <0.003
Female sex, n (%) 298 (38) 162 (34) 136 (45) 0.001 0.03 247 (37) 51 (43) 0.22 1.0
Medical history, n (%)a
Hypertension 539 (69) 312 (65) 227 (76) 0.001 0.03 446 (67) 93 (79) 0.013 0.38
Atrial fibrillation 153 (20) 77 (16) 76 (25) 0.002 0.06 117 (18) 36 (31) 0.005 0.15
Smoking history 138 (18) 98 (20) 40 (13) 0.01 0.29 125 (19) 13 (11) 0.024 0.70
Diabetes mellitus 125 (16) 59 (12) 66 (22) <0.001 <0.03 94 (14) 31 (26) 0.003 0.09
Coronary heart disease 149 (19) 75 (16) 74 (25) 0.002 0.06 113 (17) 36 (31) 0.003 0.09
Dyslipidemiab 432 (55) 280 (58) 152 (51) 0.001 0.03 381 (57) 51 (43) 0.007 0.20
Heart failure 78 (10) 38 (8) 40 (13) 0.014 0.40 57 (9) 21 (18) 0.004 0.17
Previous cerebrovascular event 152 (19) 86 (18) 66 (22) 0.16 1.0 129 (19) 23 (19) 1.0 1.0
Modified Charlson Index, median (IQR) 0 (0–1) 0 (0–1) 1 (0–2) <0.001 <0.03 0 (0–1) 1 (0–3) <0.0001 <0.003
NIHSS score at admission, median (IQR) 6 (3–13) 4 (2–7) 13 (7–17.5) <0.001 <0.03 5 (2–10) 15 (9–19) <0.001 <0.03
Laboratory values, median (IQR)
MR-proANP, pmol/L 159 (91–284) 127 (79–224) 225 (126–359) <0.001 <0.03 139 (85–253) 262 (192–420) 0.0008 0.02
Glucose, mmol/L 6.3 (5.5–7.5) 6.0 (5.4–7.2) 6.7 (5.8–8.3) <0.001 <0.03 6.2 (5.5–7.5) 6.7 (5.8–8.5) 0.0011 0.03
C-reactive protein, mg/L 3 (3–6) 3 (3–5) 3 (3–9) <0.001 <0.03 3 (3–5) 4 (3–12) <0.0001 <0.003
eGFR, mL/min/1.73 m2 75 (61–92) 78 (65–93) 70 (55–90) <0.001 <0.03 77 (63–92) 62 (52–84) <0.001 <0.03
Lesion size on MR, DWI, n (%)a,c
None detected 39 (7) 32 (9) 7 (4) 0.074 1.0 38 (8) 1 (2) 0.16 1.0
Small (1–10 cm3) 233 (43) 197 (53) 36 (22) <0.001 <0.03 226 (47) 7 (14) <0.001 <0.03
Medium (10–100 cm3) 205 (38) 128 (35) 77 (46) 0.01 0.29 182 (38) 23 (45) 0.29 1.0
Continued
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Table 1 Patient characteristics (continued)
Total
Functional outcome at 90 d Mortality at 90 d
Favorable outcome
(mRS score 0–2)
Unfavorable outcome
(mRS score 3–6) p Value Bonferroni p value Alive Dead p Value Bonferroni p value
Large (<100 cm3) 60 (11) 14 (4) 46 (28) <0.001 <0.03 40 (8) 20 (39) <0.001 <0.03
Stroke etiology (TOAST), n (%)a
Large vessel disease 109 (14) 64 (13) 45 (15) 0.46 1.0 99 (15) 10 (8) 0.06 1.0
Cardioembolic stroke 314 (40) 186 (39) 128 (43) 0.29 1.0 266 (40) 48 (41) 0.76 1.0
Small artery disease 45 (6) 40 (8) 5 (2) <0.001 <0.03 43 (7) 2 (2) 0.05 1.0
Other known 28 (4) 16 (3) 12 (4) 0.85 1.0 27 (4) 1 (1) 0.12 1.0
Unknown 216 (28) 124 (26) 92 (31) 0.14 1.0 169 (25) 47 (40) <0.004 0.12
Multiple causes 70 (9) 52 (11) 18 (6) 0.028 0.81 61 (9) 10 (8) 1.0 1.0
Treatment, n (%)a
IV thrombolysis 160 (20) 97 (20) 63 (21) 0.76 1.0 136 (21) 24 (20) 0.98 1.0
IA thrombolysis 124 (16) 47 (10) 77 (26) 0.001 0.03 93 (14) 31 (26) 0.0008 0.02
IV and IA thrombolysis 35 (4) 16 (3) 19 (6) 0.046 1.0 27 (4) 8 (7) 0.18 1.0
Abbreviations: DWI = diffusion-weighted imaging; eGFR = estimated glomerular filtration rate; IA = intra-arterial; IQR = interquartile range; MR = magnetic resonance; MR-proANP = midregional proatrial natriuretic peptide;
mRS = modified Rankin scale; NIHSS = NIH Stroke Scale; TOAST = Trial of Org 10172 in Acute Stroke Treatment.
Statistics: values are median (IQR) or percent (number). The p values were assessed with the Mann-Whitney U test and Fisher exact test. Bonferroni p values <0.05 were considered statistically significant.
a Because of rounding, percentages may not total 100.
b Dyslipidemia: of 432 patients who had dyslipidemia, 183 took statins on admission.
c Percentages refer to patients for whom information on DWI lesion was present (n = 537).
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Table 2 Multivariate logistic and Cox regression analyses for 90-day functional outcome and mortality WITH and
WITHOUT MR-proANP
With MR-proANP Without MR-proAMP
Predictors OR 95% CI p Value OR 95% CI p Value
Functional outcome
MR-proANPa 2.46 1.05–5.74 0.038 NA NA NA
Age 1.06 1.04–1.08 <0.001 1.07 1.05–1.09 <0.001
Female sex 1.19 0.78–1.82 0.41 1.18 0.78–1.80 0.44
Hypertension 0.91 0.56–1.48 0.71 0.94 0.58–1.51 0.79
History of atrial fibrillation 1.02 0.56–1.88 0.95 1.14 0.62–2.07 0.68
Diabetes mellitus 1.42 0.77–2.62 0.26 1.36 0.74–2.50 0.32
Heart failure 1.08 0.53–2.17 0.84 1.13 0.56–2.30 0.73
Modified Charlson Index 1.10 0.92–1.32 0.31 1.13 0.94–1.35 0.19
NIHSS score at admission 1.21 1.16–1.27 <0.001 1.22 1.17–1.27 <0.001
Glucosea 1.30 0.21–7.99 0.78 1.38 0.23–8.34 0.73
C-reactive proteina 1.64 0.98–2.76 0.060 1.69 1.00–2.83 0.05
eGFRa 2.16 1.16–4.02 0.016 1.70 0.95–3.03 0.072
Large lesion size on MR, DWI (<100 cm3) 3.61 1.47–8.90 0.005 3.68 1.51–9.01 0.004
Cardioembolic stroke 0.75 0.43–1.32 0.32 0.79 0.45–1.38 0.41
Small artery disease stroke 0.47 0.16–1.42 0.18 0.43 0.14–1.29 0.13
IV thrombolysis 0.59 0.34–1.03 0.06 0.58 0.33–1.01 0.05
IA thrombolysis 0.63 0.34–1.03 0.17 0.64 0.33–1.25 0.19
IV and IA thrombolysis 0.72 0.27–1.87 0.49 0.70 0.27–1.82 0.47
Pseudo-R2 0.3292
Pseudo-R2 without MR-proANP 0.3245
With MR-proANP Without MR-proAMP
Predictors Hazard ratio 95% CI p Value Hazard ratio 95% CI p Value
Mortality
MR-proANPa 6.12 2.36–15.84 0.01 NA NA NA
Age 1.03 1.01–1.05 0.014 1.04 1.02–1.06 <0.001
History of atrial fibrillation 1.18 0.67–2.07 0.57 1.35 0.77–2.38 0.30
Diabetes mellitus 2.27 1.31–3.96 0.004 2.11 1.22–3.65 0.008
Dyslipidemia 0.49 0.32–0.75 0.001 0.49 0.32–0.74 <0.001
Heart failure 1.08 0.92–1.18 0.83 1.14 0.55–2.33 0.73
Modified Charlson Index 1.04 0.96–1.18 0.53 1.05 0.93–1.19 0.43
NIHSS score at admission 1.10 1.07–1.13 <0.001 1.10 1.08–1.13 <0.001
C-reactive proteina 1.82 1.16–2.84 0.009 1.78 1.15–2.75 0.01
Glucosea 1.31 0.22–7.82 0.77 1.92 0.32–11.4 0.48
eGFRa 1.10 0.61–1.99 0.75 0.65 0.39–1.09 0.10
Small lesion size (1–10 cm3) 0.34 0.14–0.80 0.013 0.30 0.13–0.71 0.006
Continued
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outcome within 3 months (table e-2, http://links.lww.com/
WNL/A111). Accordingly, the combination of MR-proANP
with the regression model led to a modest increase in the con-
tinuous NRI of 9% (95% CI −0.2% to 37%, p = 0.62) and
categorical NRI of 1.4% (95% CI −2.4% to 5.0%, p = 0.61).
Prediction of death within 90 days after stroke
Within 90 days, 118 patients (15%) had died (table 1). MR-
proANP levels were higher among patients who died com-
pared to survivors (262 [IQR 192–420] vs 139 [IQR 85–253]
pmol/L, p < 0.001) (ﬁgure e-3, http://links.lww.com/WNL/
A110). The Kaplan-Meier survival curves of patients stratiﬁed
per MR-proANP quartiles diﬀered signiﬁcantly (p < 0.001,
log-rank test, ﬁgure e-4).
In the multivariate Cox regression model, MR-proANP was
associated with 90-daymortality with a hazard ratio of 6.12 (95%
CI 2.36–15.84, p = 0.01). Table 2 summarizes additional pre-
dictors of mortality, including heart failure and cardioembolic
stroke etiology. The multivariate models were well calibrated
Table 2 Multivariate logistic andCox regression analyses for 90-day functional outcomeandmortalityWITH andWITHOUT
MR-proANP (continued)
With MR-proANP Without MR-proAMP
Predictors Hazard ratio 95% CI p Value Hazard ratio 95% CI p Value
Large lesion size (<100 cm3) 1.21 0.66–2.22 0.54 1.19 0.65–2.18 0.57
Cardioembolic stroke 0.86 0.45–1.64 0.64 0.94 0.49–1.78 0.84
Undetermined stroke 2.62 1.43–4.80 0.002 2.26 1.26–4.08 0.007
IV thrombolysis 1.02 0.57–1.84 0.95 0.95 0.52–1.72 0.86
IA thrombolysis 0.74 0.42–1.30 0.30 0.77 0.44–1.34 0.35
IV and IA thrombolysis 1.87 0.79–4.39 0.15 1.06 0.67–3.83 0.28
Abbreviations: CI = confidence interval; DWI = diffusion-weighted imaging; eGFR = estimated glomerular filtration rate; IA = intra-arterial; MR = magnetic
resonance; MR-proANP = midregional proatrial natriuretic peptide; NA = not applicable; NIHSS = NIH Stroke Scale; OR = odds ratio.
a ORs and hazard ratio refer to a 1-unit increase in the explanatory variable and to any 10-fold increase in MR-proANP, glucose, C-reactive protein, and eGFR
(log transformed with a base of 10). All of the covariates entered in the models are listed in the table.
Table 3 ROC analyses of 90-day functional outcome and mortality
Predictors AUC 95% CI De Long testa Likelihood ratio testb
Functional outcome
MR-proANP 0.68 0.65–0.72 NA NA
NIHSS score 0.82 0.78–0.85 0.01 NA
Combined score (NIHSS score and MR-proANP) 0.83 0.80–0.86 0.07 <0.001
Model 1c 0.85 0.83–0.88 NA NA
Model 1 and MR-proANPc 0.86 0.83–0.88 0.60 <0.0071
Mortality
MR-proANP 0.73 0.68–0.78 NA NA
NIHSS score 0.80 0.77–0.84 0.01 NA
Combined score (NIHSS score and MR-proANP) 0.84 0.80–0.87 0.02 <0.01
Model 2d 0.87 0.84–0.90 NA NA
Model 2 and MR-proANPd 0.89 0.85–0.92 0.03 <0.001
Abbreviations: AUC = area under the ROC curve; CI = confidence interval; MR-proANP =midregional proatrial natriuretic peptide; NA = not applicable; NIHSS =
NIH Stroke Scale; ROC = receiver operating characteristics.
a To compare the AUCs of 2 different single variables, the De Long test was used.
b To compare the AUCs of nested vs whole models, the likelihood ratio test was used.
c Model 1 (age, NIHSS score, large lesion size, estimated glomerular filtration rate, cardioembolic stroke, IV thrombolysis, intra-arterial thrombolysis, IV/intra-
arterial thrombolysis, heart failure), multivariate logistic regression model, is presented in table 2 (top).
d Model 2 (age, dyslipidemia, C-reactive protein, diabetesmellitus, NIHSS score, small lesions size, unclear stroke, cardioembolic stroke, IV thrombolysis, intra-
arterial thrombolysis, IV/intra-arterial thrombolysis, heart failure), Cox regression model, is presented in table 2 (bottom).
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according to the goodness-of-ﬁt test [Groennesby and Borgan
test χ2(1) = 1.4; p = 0.2]. No signiﬁcant interactions were found
across diﬀerent subgroups for the prediction of mortality.
The overall discriminative ability of MR-proANP to distinguish
survivors from nonsurvivors, assessed with the AUC, was 0.73
(95%CI 0.68–0.78).WhenMR-proANPwas combinedwith the
Cox regression model, the discriminatory accuracy increased
from an AUC of 0.87 (95% CI 0.84–0.90) to 0.89 (95% CI
0.85–0.92, p < 0.001) (table 3 and ﬁgures e-5 and e-6, http://
links.lww.com/WNL/A110). An MR-proANP level of 163
pmol/L had a sensitivity of 81% and a speciﬁcity of 56% for death
within 3 months (table e-2, http://links.lww.com/WNL/A111).
The combination ofMR-proANPwith the Cox regressionmodel
led to a continuous NRI of 49% (95% CI 26%–78%, p < 0.001)
and categorical NRI of 16% (95% CI 9.5%–29.0%, p < 0.001).
Identification of cardioembolic stroke and
atrial fibrillation
Median MR-proANP levels were almost twice as high in
patients with cardioembolic stroke compared to other stroke
Table 4 Baseline characteristics stratified by cardioembolic stroke
Total No cardioembolic stroke Cardioembolic stroke p Value Bonferroni p value
No. (%) 783 (100) 469 (60) 314 (40)
Demographic data
Age, median (IQR), y 71 (61–80) 70 (59–79) 73 (62–81) 0.017 0.34
Women, n (%)a 298 (38) 160 (34) 138 (44) 0.007 0.14
Medical history, n (%)a
Hypertension 539 (69) 311 (66) 228 (73) 0.07 1.0
Atrial fibrillation 153 (20) 18 (4) 135 (43) <0.001 <0.02
Smoking 138 (18) 98 (21) 40 (13) 0.007 0.14
Diabetes mellitus 125 (16) 81 (17) 44 (14) 0.19 1.0
Coronary heart disease 149 (19) 17 (4) 132 (44) <0.001 <0.02
Heart failure 78 (10) 30 (6) 48 (15) <0.001 <0.02
Dyslipidemia 432 (55) 282 (60) 150 (48) 0.002 0.04
Previous cerebrovascular event 152 (19) 96 (21) 56 (18) 0.41 1.0
Clinical data, median (IQR)
NIHSS score at admission 6 (3–13) 6 (3–12) 6.5 (3–14.5) 0.11 1.0
Modified Charlson Index 0 (0–1) 0 (0–1) 1 (0–1) 0.36 1.0
Laboratory values, median (IQR)
MR-proANP, pmol/L 159 (91–284) 128 (84–216) 233 (116–359) <0.001 <0.02
Glucose, mmol/L 6.3 (5.5–7.5) 6.3 (5.6–7.5) 6.2 (5.4–7.6) 0.25 1.0
C-reactive Protein, mg/L 3 (3–6) 3 (3–5) 3 (3–7) 0.17 1.0
eGFR, mL/min/1.73 m2 75 (61–92) 76 (63–93) 73 (58–90) 0.03 0.6
Lesion size on MR, DWI, n (%)a,b
None detected 39 (7) 29 (9) 10 (5) 0.17 1.0
Small (1–10 cm3) 233 (43) 158 (46) 75 (39) 0.09 1.0
Medium (10–100 cm3) 205 (38) 117 (34) 88 (45) 0.013 0.26
Large (<100 cm3) 60 (11) 38 (11) 22 (11) 1.00 1.0
Abbreviations: DWI = Diffusion weighted imaging; eGFR = estimated glomerular filtration rate; IQR = interquartile range; MR = magnetic resonance; MR-
proANP = midregional proatrial natriuretic peptide; NIHSS = NIH Stroke Scale.
Statistics: values are median (IQR) or percent (number). The p values were assessed with the Mann-Whitney U test and Fisher exact test. Bonferroni p values
<0.05 were considered statistically significant.
a Because of rounding, percentages may not total 100.
b Percentages refer to patients for whom information on DWI lesion was present (n = 537).
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etiologies (tables 4 and 5). In the multivariate logistic model,
MR-proANP was associated with cardioembolic stroke (OR
2.10, 95% CI 1.11–3.97, p = 0.023). The multivariate models
were well calibrated (p = 0.7).
MR-proANP levels ≥255 pmol/L had a sensitivity of 44% and
a speciﬁcity of 82% for a cardioembolic etiology (table e-2,
http://links.lww.com/WNL/A111). Adding MR-proANP to
the multivariate regression model increased the discrimina-
tory accuracy for cardioembolic from an AUCof 0.74 (95%CI
0.71–0.78) to 0.76 (95% CI 0.72–0.80, p = 0.002) (table e-3).
However, the combination of MR-proANP with the logistic
regression model led to a nonsigniﬁcant continuous NRI of
20% (95% CI 4.9%–4.6%, p = 0.43) and a categorical NRI of
6.3% (95% CI −5.7% to 21.4%, p = 0.19).
Among patients with diagnosis of atrial ﬁbrillation at hospital
discharge, MR-proANP levels were more than twice as high as
in patients without atrial ﬁbrillation (table e-4, http://links.
lww.com/WNL/A111). In the multivariate model, MR-
proANP was independently associated with diagnosis of atrial
ﬁbrillation at hospital discharge (OR 18.35, 95% CI
7.94–42.45, p < 0.001) (table e-5). MR-proANP levels ≥289
pmol/L had a speciﬁcity of 86% and a sensitivity of 48% for the
diagnosis of atrial ﬁbrillation at hospital discharge (table e-2).
Adding MR-proANP to signiﬁcant predictors of atrial ﬁbrilla-
tion increased the AUC from 0.70 (95% CI 0.67–0.74) to 0.79
(95% CI 0.76–0.82, p < 0.001) (table e-6), leading to a con-
tinuous NRI of 78% (95% CI 60%–89%, p < 0.001) and
a categorical NRI of 39% (95% CI 27%–55%, p < 0.001).
Discussion
In this prospective multicenter cohort of acute ischemic
stroke patients, MR-proANP was an independent predictor of
functional outcome, mortality, cardioembolic stroke etiology,
and atrial ﬁbrillation. Of note, across the analyzed subgroups,
the association between MR-proANP and the outcome vari-
ables remained signiﬁcant. When MR-proANP was added to
prognostic models using diﬀerent statistical methods
(i.e., comparison of AUCs, NRI, and change in pseudo-R2),
we found an improvement for mortality and the identiﬁcation
of atrial ﬁbrillation. Our multicenter study conﬁrms and
extends the conclusions of a previous single-center cohort
study of 362 patients with acute ischemic stroke, which also
found an independent association between MR-proANP and
mortality, as well as cardioembolic stroke.5 Because of the
larger sample size of the current study, it was possible to adjust
for several prognostic factors, to compare subgroups, and to
assess the incremental value of MR-proANP beyond the most
important demographic and vascular risk factors.
In stroke research, brain natriuretic peptide (BNP) has been
shown to predict all-cause mortality and, in some studies,
functional outcome.5,15 In a meta-analysis of 3,498 patients
with ischemic stroke, BNP and N-terminal probrain natri-
uretic peptide (NT-proBNP) added information to clinical
predictors (NIHSS score, age, sex) for the prediction of
mortality (NRI 8.1%) but not for functional outcome,16 which
is in line with our observation that MR-proANP had a better
prognostic accuracy for mortality rather than functional out-
come. The pathophysiologic relationship between elevated
levels of natriuretic peptides and stroke prognosis is still un-
clear. The highest ANP levels within the CNS are found in the
hypothalamus and septum.17 Activation of the hypothalamus-
pituitary-adrenal axis is associated with elevated levels of na-
triuretic peptides. High cortisol, copeptin, and natriuretic
peptide values predict long-term mortality after ischemic
stroke, suggesting that a neurohumoral disturbance is linked
to unfavorable outcome.5,18 In addition, ANP is secreted by
Table 5 Multivariate logistic regression analyses for cardioembolic stroke WITH and WITHOUT MR-proANP
With MR-proANP Without MR-proAMP
Predictors OR 95% CI p Value OR 95% CI p Value
MR-proANP, pmol/La 2.10 1.11–3.97 0.023 NA NA NA
Age 0.98 0.97–1.00 0.023 0.99 0.97–1.00 0.14
Female sex 1.35 0.95–1.91 0.09 1.43 1.01–2.02 0.041
History of atrial fibrillation 15.34 8.87–26.53 <0.001 17.44 10.2–29.9 <0.001
Smoking 0.80 0.51–1.27 0.35 0.77 0.48–1.21 0.27
Dyslipidemia 0.70 0.51–1.27 0.35 0.69 0.50–0.97 0.035
Heart failure 1.78 0.99–3.18 0.053 2.07 1.18–3.66 0.012
Pseudo-R2 0.2016
Pseudo-R2 without MR-proANP 0.1964
Abbreviations: CI = confidence interval; MR-proANP = midregional proatrial natriuretic peptide; NA = not applicable; OR = odds ratio.
a OR refers to a 1-unit increase in the explanatory variable and to any 10-fold increase in MR-proANP (log transformed with a base of 10). All of the covariates
entered in the model are listed in the table.
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atrial myocytes in response to diﬀerent stimuli such as atrial
distension, angiotensin II stimulation, endothelin, and sym-
pathetic stimulation.19,20 The prohormone of ANP, known as
MR-proANP, has a longer half-life and makes serum meas-
urements more feasible.21
For the diagnosis of acute heart failure, MR-proANP has been
shown to be noninferior to BNP and seemed to improve the
diagnostic accuracy of BNP levels between 100 and 500 pg/
mL.22 In chronic heart failure, with regard to mortality,
MR-proANP outperformed BNP and NT-proBNP. The
proportion of explained variance (4.36%) showed that MR-
proANP was a signiﬁcantly stronger predictor of death than
either NT-proBNP (2.47%, p < 0.0001) or BNP (2.42%, p <
0.0001). Both the high biological stability of MR-proANP and
a new assay technology are potential explanations for these
ﬁndings.23
The independent association of natriuretic peptides with
cardioembolic stroke (after adjustment for age and evident
atrial ﬁbrillation) could be explained through an underlying
atrial cardiopathy, which can presumably anticipate even atrial
ﬁbrillation.24 Thus, ANP may be a potential blood marker of
atrial cardiopathy, which is also associated with cardioembolic
stroke.24 There may even be a causal relationship of ANP with
the development of atrial ﬁbrillation because individuals with
familial atrial ﬁbrillation demonstrate a frameshift mutation in
the gene encoding ANP.25 Because up to 30% of patients with
cryptogenic stroke may have undetected paroxysmal atrial
ﬁbrillation or other unrecognized cardioembolic sources,26
MR-proANP levels might help identify patients who will
beneﬁt from prolonged cardiac rhythm monitoring or oral
anticoagulants for recurrence prophylaxis. However, among
patients with strokes initially considered cryptogenic, additional
studies are needed to assess the association of MR-proANP with
paroxysmal atrial ﬁbrillation and cardioembolism.
This study has limitations. First, the study is lacking a direct
comparison of MR-proANP with other natriuretic peptides.
Second, the proportion of patients with cardioembolic stroke
was somewhat higher compared to other epidemiologic
studies. Possible explanations include referral bias, because
patients with cardioembolic stroke tend to have more severe
strokes and be referred to tertiary care centers like the ones
participating in this study, and a higher detection rate of
cardioembolic sources due to extensive cardiac workup (al-
most half of the patients underwent transesophageal echo-
cardiography). Third, no follow-up data on the detection of
atrial ﬁbrillation after hospitalization were available, leaving
the question of whether MR-proANP would help reclassify
cryptogenic into cardioembolic stroke. Fourth, some baseline
variables were missing, including the proportion of patients
with anterior vs posterior circulation and the frequency of large
vessel occlusion, which may contribute to outcome prediction.
Fifth, MR-proANP was associated not only with mortality but
also with other factors such as age, NIHSS score, infarct size,
hypertension, and diabetes mellitus, which were adjusted for
with a Cox regression model. However, residual confounding
eﬀects cannot be excluded. Finally, the interrater agreement of
the 2 raters of DWI lesion volumes was not available.
In the emergency setting, MR-proANP can improve the risk
stratiﬁcation for 90-day mortality after stroke. Higher MR-
proANP levels were also associated with cardioembolic stroke
etiology and, even more strongly, atrial ﬁbrillation. In the
future, MR-proANP may facilitate the selection of patients
who will beneﬁt from prolonged cardiac rhythm monitoring
and anticoagulation.
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Study question
Canmidregional proatrial natriuretic peptide (MR-proANP) levels within the ﬁrst
24 hours of ischemic stroke onset improve the prediction of 90-day mortality,
functional outcomes, and cardioembolic stroke etiology?
Summary answer
TheMR-proANP level was an independent predictor of functional outcome,
mortality, cardioembolic stroke etiology, and atrial ﬁbrillation; however, the
inclusion of MR-proANP levels improved prognostic models for mortality
and atrial ﬁbrillation only.
What is known and what this article adds
Previous single-center studies have reported that inclusion of MR-proANP
levels improves the discriminatory ability of the NIH Stroke Scale (NIHSS)
score for 90-day mortality. In this multicenter study, we veriﬁed the prog-
nostic utility of MR-proANP levels regarding several outcome measures.
Participants and setting
This prospective, multicenter cohort study included 788 consecutive patients
(median age 71 years; 62% men) admitted to the emergency departments of
participating tertiary centers within 24 hours of acute ischemic stroke onset.
Design, size, and duration
Outcomes of interest included 90-day mortality, unfavorable outcomes
(modiﬁed Rankin Scale score >2 points), diagnoses of cardioembolic stroke
etiology during hospitalization, and atrial ﬁbrillation. Blood samples for the
assessment of MR-proANP levels were obtained within 24 hours of symp-
tom onset. Regression models and the net reclassiﬁcation index (NRI) were
used to estimate the additive beneﬁt of MR-proANP levels to traditional
outcome predictors.
Main results and the role of chance
Inclusion of MR-proANP levels increased the discriminatory accuracy of
mortality and atrial ﬁbrillation prediction, but not of functional outcome and
cardioembolic etiology. The NRI of MR-proANP for mortality was 49% (95%
conﬁdence interval [CI] 26%–78%, p < 0.001), and for atrial ﬁbrillation 78%
(95% CI 60%–89%, p < 0.001). While MR-proANP levels ≥163 pmol/L had
a speciﬁcity of 56% and a sensitivity of 81% for 90-day mortality, levels ≥289
pmol/L had a speciﬁcity of 86% and sensitivity of 48% for atrial ﬁbrillation.
Bias, confounding, and other reasons for caution
MR-proANP levels were not compared with levels of other natriuretic
peptides. Residual confounding eﬀects of associations betweenMR-proANP
levels and other factors cannot be excluded.
Generalizability to other populations
Because of the study’s multicenter design, and broad inclusion criteria, the
results may be generalizable to various populations of patients with stroke.
Study funding/potential competing interests
This study was supported by the Swiss National Science Foundation, a De
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Table Multivariable logistic regression analyses for the
diagnosis of atrial fibrillation at hospital discharge
WITH and WITHOUT MR-proANP
Predictors
Odds
ratio 95% CI
p
Value
Odds
ratio 95% CI
p
Value
MR-proANP,
pmol/La
18.35 7.94–42.45 <0.001 NA NA —
Age, y 1.03 1.02–1.05 <0.001 1.05 1.03–1.07 <0.001
Female sex 1.37 0.92–2.03 0.12 1.37 0.94–2.00 0.10
Hypertension 1.28 0.80–2.04 0.31 1.48 0.95–2.31 0.084
Smoking 0.52 0.28–0.95 0.032 0.51 0.28–0.91 0.023
Heart failure 1.46 0.77–2.76 0.25 1.79 0.96–3.36 0.07
Modified
Charlson Index
0.92 0.78–1.05 0.17 0.96 0.83–1.11 0.56
NIHSS at
admission
1.01 0.98–1.04 0.50 1.03 0.99–1.05 0.07
eGFR, mL/
min/1.73 m2a
1.51 0.86–2.63 0.15 0.71 0.43–1.17 0.17
Small lesion
size on MR,
DWI
(1–10 mm3)
0.67 0.42–1.07 0.096 0.59 0.38–0.93 0.023
Pseudo-R2
Pseudo-R2
0.2047
Pseudo-R2
without MR-
proANP
0.1421
Abbreviations: DWI = diffusion weighted imaging; eGFR = estimated
glomerular filtration rate; MR = magnetic resonance; MR-proANP =
midregional proatrial natriuretic peptide; NA = not applicable; NIHSS =
NIH Stroke Scale.
a Odds ratio refers to a 1-unit increase in the explanatory variable and to any
10-fold increase in MR-proANP and eGFR (log-transformed with a base of
10). All of the covariates entered in the models are listed in the table.
A draft of the short-form article was written by D. Drobish, a writer with Editage, a division of Cactus Communications. The authors of the full-
length article and the journal editors edited and approved the ﬁnal version.
*These authors contributed equally to this work.
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CORRECTIONS
Midregional proatrial natriuretic peptide improves risk stratiﬁcation
after ischemic stroke: Association with mortality and
cardioembolic etiology
Neurology® 2018;91:637. doi:10.1212/WNL.0000000000005190
In the article “Midregional proatrial natriuretic peptide improves risk stratiﬁcation after
ischemic stroke: Association with mortality and cardioembolic etiology” by G.M. De Marchis
et al.,1 the version published ahead of print on January 10, 2018, contained some errors. The
sixth sentence of the Abstract should specify “continuous net reclassiﬁcation index (cNRI),” and
the ninth sentence should report the signiﬁcance of cNRI of atrial ﬁbrillation at (78%, 95% CI
60%–89%, p < 0.001). In the Results section, the third sentence has been changed to “The
median age of the cohort was 71 (IQR 61–80) years, and 298 (38%) were women.” Under the
subsection “Prediction of functional outcome after 3 months,” the ﬁrst sentence of the second
paragraph should report “(AUC change from 0.85 [95% CI 0.83–0.88] to 0.86 [95% CI
0.83–0.88], p < 0.0071).” The last sentence of the Results section should specify “…a contin-
uous NRI of 78%.” The title for table 2 should read, “Multivariate logistic and Cox regression
analyses for 90-day functional outcome and mortality WITH and WITHOUT MR-proANP.”
In table 4, the number (n) and percentage (%) values were reversed from row 3 through row 12,
and in table 5, row 7 should have a p value of 0.35 (for dyslipidemia), rather than 0.035 as
originally published. Corrected text and tables were published in the ﬁnal version on February
6, 2018. The authors regret the errors.
Reference
1. De Marchis GM, Schneider J, Weck A, et al. Midregional proatrial natriuretic peptide improves risk stratiﬁcation after ischemic stroke:
association with mortality and cardioembolic etiology. Neurology 2018;90:e455–e465.
Eteplirsen treatment for Duchenne muscular dystrophy: Exon
skipping and dystrophin production
Neurology® 2018;91:637. doi:10.1212/WNL.0000000000005979
In the article “Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and
dystrophin production” by J.S. Charleston et al.,1 the Acknowledgment is incomplete. It should
also include “The authors also gratefully acknowledge Dr. Steven A. Moore, the University of
Iowa Hospitals and Clinics Histology Laboratory, and the IowaWellstoneMuscular Dystrophy
Cooperative Research Center (NIH grant U54, NS053672) for providing frozen sections of
non-dystrophic control muscle biopsies, Becker muscular dystrophy muscle biopsies, and
untreated DMD biopsy samples from the PROMOVI clinical study described in this manu-
script. Dr. Moore also assisted in establishing criteria for deﬁning dystrophin positive muscle
ﬁbers.” The authors regret the omission.
Reference
1. Charleston JS, Schnell FJ, Dworzak J, et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin
production. Neurology 2018;90:e2146–e2154.
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